These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

210 related items for PubMed ID: 16495253

  • 21. Pharmacokinetics of fosamprenavir plus ritonavir in human immunodeficiency virus type 1-infected adult subjects with hepatic impairment.
    Pérez-Elías MJ, Morellon ML, Ortega E, Hernández-Quero J, Rodríguez-Torres M, Clotet B, Felizarta F, Gutiérrez F, Pineda JA, Nichols G, Lou Y, Wire MB.
    Antimicrob Agents Chemother; 2009 Dec; 53(12):5185-96. PubMed ID: 19667283
    [Abstract] [Full Text] [Related]

  • 22. Pharmacokinetics and safety of amprenavir and ritonavir following multiple-dose, co-administration to healthy volunteers.
    Sadler BM, Piliero PJ, Preston SL, Lloyd PP, Lou Y, Stein DS.
    AIDS; 2001 May 25; 15(8):1009-18. PubMed ID: 11399983
    [Abstract] [Full Text] [Related]

  • 23. SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir /ritonavir versus twice-daily nelfinavir in naive HIV-1-infected patients.
    Gathe JC, Ive P, Wood R, Schürmann D, Bellos NC, DeJesus E, Gladysz A, Garris C, Yeo J.
    AIDS; 2004 Jul 23; 18(11):1529-37. PubMed ID: 15238771
    [Abstract] [Full Text] [Related]

  • 24. Population pharmacokinetic modeling and simulation of amprenavir following fosamprenavir/ritonavir administration for dose optimization in HIV infected pediatric patients.
    Barbour AM, Gibiansky L, Wire MB.
    J Clin Pharmacol; 2014 Feb 23; 54(2):206-14. PubMed ID: 25272370
    [Abstract] [Full Text] [Related]

  • 25. Coadministration of esomeprazole with fosamprenavir has no impact on steady-state plasma amprenavir pharmacokinetics.
    Shelton MJ, Ford SL, Borland J, Lou Y, Wire MB, Min SS, Xue ZG, Yuen G.
    J Acquir Immune Defic Syndr; 2006 May 23; 42(1):61-7. PubMed ID: 16639341
    [Abstract] [Full Text] [Related]

  • 26. A 42-week open-label study to assess the pharmacokinetics, antiretroviral activity, and safety of amprenavir or amprenavir plus ritonavir in combination with abacavir and lamivudine for treatment of HIV-infected patients.
    Wood R, Eron J, Arasteh K, Teofilo E, Trepo C, Livrozet JM, Yeo J, Millard J, Wire MB, Naderer OJ.
    Clin Infect Dis; 2004 Aug 15; 39(4):591-4. PubMed ID: 15356829
    [Abstract] [Full Text] [Related]

  • 27. Pharmacokinetic interaction between maraviroc and fosamprenavir-ritonavir: an open-label, fixed-sequence study in healthy subjects.
    Vourvahis M, Plotka A, Mendes da Costa L, Fang A, Heera J.
    Antimicrob Agents Chemother; 2013 Dec 15; 57(12):6158-64. PubMed ID: 24080663
    [Abstract] [Full Text] [Related]

  • 28. Fosamprenavir (GW433908)/ritonavir in HIV-infected patients: efficacy and safety results from the Spanish Expanded Access Program.
    Pérez-Elias MJ, Sánchez-Conde M, Soriano V, Mallolas J, Luque I, Rodríguez-Alcántara F, Fosamprenavir Expanded Access Program Group.
    Enferm Infecc Microbiol Clin; 2009 Jan 15; 27(1):28-32. PubMed ID: 19218000
    [Abstract] [Full Text] [Related]

  • 29. Effects of ritonavir-boosted darunavir vs. ritonavir-boosted atazanavir on lipid and glucose parameters in HIV-negative, healthy volunteers.
    Tomaka F, Lefebvre E, Sekar V, Van Baelen B, Vangeneugden T, Vandevoorde A, Diego Miralles G.
    HIV Med; 2009 May 15; 10(5):318-27. PubMed ID: 19210693
    [Abstract] [Full Text] [Related]

  • 30. Fosamprenavir/ritonavir plus tenofovir does not affect amprenavir pharmacokinetics: no effect of tenofovir.
    Kurowski M, Walli RK, Breske A, Kruse G, Stocker H, Banik N, Richter H, Mazur D.
    AIDS; 2007 Jun 19; 21(10):1368-70. PubMed ID: 17545717
    [Abstract] [Full Text] [Related]

  • 31. Amprenavir or fosamprenavir plus ritonavir in HIV infection: pharmacology, efficacy and tolerability profile.
    Arvieux C, Tribut O.
    Drugs; 2005 Jun 19; 65(5):633-59. PubMed ID: 15748098
    [Abstract] [Full Text] [Related]

  • 32. Atazanavir and lopinavir/ritonavir: pharmacokinetics, safety and efficacy of a promising double-boosted protease inhibitor regimen.
    Ribera E, Azuaje C, Lopez RM, Diaz M, Feijoo M, Pou L, Crespo M, Curran A, Ocaña I, Pahissa A.
    AIDS; 2006 May 12; 20(8):1131-9. PubMed ID: 16691064
    [Abstract] [Full Text] [Related]

  • 33. Genotypic resistance analysis of the virological response to fosamprenavir-ritonavir in protease inhibitor-experienced patients in CONTEXT and TRIAD clinical trials.
    Marcelin AG, Flandre P, Molina JM, Katlama C, Yeni P, Raffi F, Antoun Z, Ait-Khaled M, Calvez V.
    Antimicrob Agents Chemother; 2008 Dec 12; 52(12):4251-7. PubMed ID: 18852278
    [Abstract] [Full Text] [Related]

  • 34. Pharmacokinetic profile and tolerability of indinavir-ritonavir combinations in healthy volunteers.
    Saah AJ, Winchell GA, Nessly ML, Seniuk MA, Rhodes RR, Deutsch PJ.
    Antimicrob Agents Chemother; 2001 Oct 12; 45(10):2710-5. PubMed ID: 11557459
    [Abstract] [Full Text] [Related]

  • 35. The plasma and intracellular steady-state pharmacokinetics of lopinavir/ritonavir in HIV-1-infected patients.
    Crommentuyn KM, Mulder JW, Mairuhu AT, van Gorp EC, Meenhorst PL, Huitema AD, Beijnen JH.
    Antivir Ther; 2004 Oct 12; 9(5):779-85. PubMed ID: 15535416
    [Abstract] [Full Text] [Related]

  • 36. Similar virologic and immunologic efficacy with fosamprenavir boosted with 100 mg or 200 mg of ritonavir in HIV-infected patients: results of the LESS trial.
    Cohen C, Dejesus E, Lamarca A, Young B, Yau L, Patel L, Vavro C, Wire MB, Wannamaker P, Shaefer M.
    HIV Clin Trials; 2010 Oct 12; 11(5):239-47. PubMed ID: 21126954
    [Abstract] [Full Text] [Related]

  • 37. The effect of low-dose ritonavir monotherapy on fasting serum lipid concentrations.
    Shafran SD, Mashinter LD, Roberts SE.
    HIV Med; 2005 Nov 12; 6(6):421-5. PubMed ID: 16268824
    [Abstract] [Full Text] [Related]

  • 38. Evaluation of pharmacokinetic interaction between cetirizine and ritonavir, an HIV-1 protease inhibitor, in healthy male volunteers.
    Peytavin G, Gautran C, Otoul C, Cremieux AC, Moulaert B, Delatour F, Melac M, Strolin-Benedetti M, Farinotti R.
    Eur J Clin Pharmacol; 2005 Jun 12; 61(4):267-73. PubMed ID: 15889300
    [Abstract] [Full Text] [Related]

  • 39. Effect of fosamprenavir-ritonavir on the pharmacokinetics of dolutegravir in healthy subjects.
    Song I, Borland J, Chen S, Peppercorn A, Wajima T, Piscitelli SC.
    Antimicrob Agents Chemother; 2014 Nov 12; 58(11):6696-700. PubMed ID: 25155604
    [Abstract] [Full Text] [Related]

  • 40. Effect of rifampin on steady-state pharmacokinetics of atazanavir with ritonavir in healthy volunteers.
    Burger DM, Agarwala S, Child M, Been-Tiktak A, Wang Y, Bertz R.
    Antimicrob Agents Chemother; 2006 Oct 12; 50(10):3336-42. PubMed ID: 17005814
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.